The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.

High risk children (with family history of myopia) with low hyperopia or low myopia will be randomized to atropine or placebo, with 2 -2.5 year treatment and 1 year washout.

Inclusion criteria

1. One parent with myopia (<-3D in at least one eye)
2. SE +1.00D to -1.50D
3. Astigmatism < = 1.50D
4. Distance vision logMAR 0.2 or better in both eyes
5. Intraocular pressure of not greater than 21 mmHg
6. No allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride

Exclusion Criteria:

1. Any eye or systemic disease that affect vision or refractive error
2. Conditions where topical atropine contraindicated
3. Previous use of atropine or pirenzepine
4. Known past/current amblyopia or strabismus